Rat PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Antibody Pair (STJAP00098)

SKU:
STJAP00098-50

Shipping:
Free Shipping
Current Stock:
Host: Mouse/Rabbit
Applications: ELISA
Reactivity: Rat
Note: FOR SCIENTIFIC EDUCATIONAL RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR OTHER MEDICAL APPLICATIONS.
Short Description: This PCSK9 antibody pair contains complimentary capture and detection antibodies, which work together under the principals of the Sandwich ELISA.
Clonality: Monoclonal/Monoclonal
Conjugation: Unconjugated/Biotin
Formulation: Capture Buffer: PBS with 0.04% Proclin 300, 50% glycerol, pH 7.4.
Detection Buffer: PBS with 0.04% Proclin 300, 50% glycerol, pH 7.4.
Purification: Capture Purification: Protein A.
Detection Purification: Protein A.
Concentration: 0.5 mg/mL
Storage Instruction: Store at-20°C for long term, and avoid freeze-thaw cycles.
Gene Symbol: Pcsk9
Gene ID: 298296
Uniprot ID: PCSK9_RAT
Immunogen: Capture immunogen: Recombinant Rat PCSK9 protein.
Detection Immunogen: Recombinant Rat PCSK9 protein.
Post Translational Modifications Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation. Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Phosphorylation protects the propeptide against proteolysis.
Function Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Protein Name Proprotein Convertase Subtilisin/Kexin Type 9
Neural Apoptosis-Regulated Convertase 1
Narc-1
Proprotein Convertase 9
Pc9
Subtilisin/Kexin-Like Protease Pc9
Database Links Reactome: R-RNO-381426
Reactome: -RNO-8866427
Reactome: -RNO-8957275
Reactome: -RNO-8964038
Cellular Localisation Cytoplasm
Secreted
Endosome
Lysosome
Cell Surface
Endoplasmic Reticulum
Golgi Apparatus
Autocatalytic Cleavage Is Required To Transport It From The Endoplasmic Reticulum To The Golgi Apparatus And For The Secretion Of The Mature Protein
Localizes To The Endoplasmic Reticulum In The Absence Of Ldlr And Colocalizes To The Cell Surface And To The Endosomes/Lysosomes In The Presence Of Ldlr
The Sorting To The Cell Surface And Endosomes Is Required In Order To Fully Promote Ldlr Degradation
Alternative Antibody Pair Names Proprotein Convertase Subtilisin/Kexin Type 9 antibody pair
Neural Apoptosis-Regulated Convertase 1 antibody pair
Narc-1 antibody pair
Proprotein Convertase 9 antibody pair
Pc9 antibody pair
Subtilisin/Kexin-Like Protease Pc9 antibody pair
Pcsk9 antibody pair
Narc1 antibody pair

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance